Biotech Startups: Move Slow and Fix Things — Stanford Biotechnology Group
Startups are the primary source of biotechnology innovation. But funding for biotech entrepreneurs has been on a risky trajectory. What lies ahead? In our latest Biotech Insights blog, Joel Bateman, first-year MBA student at the Stanford GSB argues that incorrect parallels to the t
Biotech Startups: Move Slow and Fix Things Mar 10 Written By Joel Bateman Startups are the primary source of biotechnology innovation. But funding for biotech entrepreneurs has been on a risky trajectory. What lies ahead? In our latest Biotech Insights blog, Joel Bateman, first-year MBA student at the Stanford GSB argues that incorrect parallels to the tech industry and perceived falling costs associated with biotech startups have led to riskier and earlier funding for biotech startups. He outlines implications for the years ahead and offers ideas for biotech entrepreneurs to navigate the bump
saved by
related reading
- Tech vs Biotech - Celine Haliouacelinehh.com
- Fundraising for Founder-led Biotech – Matt Krisiloffmattkrisiloff.com
- The Biotech Delusion: Things No One Wants to Admitmattshlosberg.substack.com
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Early-Stage Biotech Value Creation: The Roles of Equity and Partnershipsleadershipandbiotechnology.blogspot.com
- Anatomy of a Biotech Business Development Deal | Andreessen Horowitza16z.com
- Biotech’s Dulcius Ex Asperis: The Way Through This Downturn - RApportrapport.bio
- The future of biotech is founder-led | Tony Kulesa | Pillar VCpillar.vc
- The Stanford Freshmen Who Think They Rule the World - The Atlantictheatlantic.com
- VC-Backed Startups are Low Statusmhdempsey.substack.com
- How To Invest In Startups - Sam Altmanblog.samaltman.com
- Rebuild Biotech for the AI Era | Benchlingbenchling.com